Evidence
Nat Commun. 2023 May 4;14(1):2573. doi: 10.1038/s41467-023-38165-6.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world. High levels of free fatty acids in the liver impair hepatic lysosomal acidification and reduce autophagic flux. We investigate whether restoration of lysosomal function in NAFLD recovers autophagic flux, mitochondrial function, and insulin sensitivity. Here, we report the synthesis of novel biodegradable acid-activated acidifying nanoparticles (acNPs) as a lysosome targeting treatment to restore lysosomal acidity and autophagy. The acNPs, composed of fluorinated polyesters, remain inactive at plasma pH, and only become activated in lysosomes after endocytosis. Specifically, they degrade at pH of ~6 characteristic of dysfunctional lysosomes, to further acidify and enhance the function of lysosomes. In established in vivo high fat diet mouse models of NAFLD, re-acidification of lysosomes via acNP treatment restores autophagy and mitochondria function to lean, healthy levels. This restoration, concurrent with reversal of fasting hyperglycemia and hepatic steatosis, indicates the potential use of acNPs as a first-in-kind therapeutic for NAFLD.
PMID:37142604 | DOI:10.1038/s41467-023-38165-6
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease
🌐 90 Days
VR Related Evidence Matrix
- Optogenetic manipulation of lysosomal physiology and autophagy-dependent clearance of amyloid beta
- CASM mediates LRRK2 recruitment and activation under lysosomal stress
- Organophosphate ester flame retardants and plasticizers affect the phenotype and function of HepG2 liver cells
- Lysosomal Channels as New Molecular Targets in the Pharmacological Therapy of Neurodegenerative Diseases via Autophagy Regulation
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Lysosomal dysfunction and overload of nucleosides in thymidine phosphorylase deficiency of MNGIE
- Deficiency of ADAR2 ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in obese mice
- Reduction of spermine synthase enhances autophagy to suppress Tau accumulation
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Human cytomegalovirus degrades DMXL1 to inhibit autophagy, lysosomal acidification, and viral assembly
- The gut-liver axis in fatty liver disease: role played by natural products
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- PINK1/Park2-Mediated Mitophagy Relieve Non-Alcoholic Fatty Liver Disease
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Exploring Bile-Acid Changes and Microflora Profiles in Chicken Fatty Liver Disease Model
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- The Regulatory Mechanism of Smilax China L. Saponins against Nonalcoholic Fatty Liver Is Revealed by Metabolomics and Transcriptomics
- Lactiplantibacillus plantarum ZDY2013 Inhibits the Development of Non-Alcoholic Fatty Liver Disease by Regulating the Intestinal Microbiota and Modulating the PI3K/Akt Pathway
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Spatial genomics: mapping human steatotic liver disease
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
- Bacteroides fragilis aggravates high-fat diet-induced non-alcoholic fatty liver disease by regulating lipid metabolism and remodeling gut microbiota
- Toxic gain-of-function mechanisms in C9orf72 ALS-FTD neurons drive autophagy and lysosome dysfunction
- Emerging roles of RNA-binding proteins in fatty liver disease
- Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease
- A study on the treatment effects of Crataegus pinnatifida polysaccharide on non-alcoholic fatty liver in mice by modulating gut microbiota
- Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis
- Novel blood and tissue-based mitochondrial D-loop mutations detected in an Iranian NAFLD patient cohort
- Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation
- Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- ROS-mediated lysosomal membrane permeabilization and autophagy inhibition regulate bleomycin-induced cellular senescence
- Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Bacteroides and NAFLD: pathophysiology and therapy
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Inflammatory liver diseases and susceptibility to sepsis
- Natural compounds proposed for the management of non-alcoholic fatty liver disease
Evidence Blueprint
Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease
🌐 365 Days
VR Related Evidence Matrix
- Naringin Protects against Non-Alcoholic Fatty Liver Disease by Promoting Autophagic Flux and Lipophagy
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Cathepsin D mediates prenatal caffeine exposure-caused NAFLD susceptibility in male rat offspring by regulating autophagy
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- Metabolic changes and propensity for inflammation, fibrosis, and cancer in livers of mice lacking lysosomal acid lipase
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Optogenetic manipulation of lysosomal physiology and autophagy-dependent clearance of amyloid beta
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
- Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
- Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome
- AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression
- Modelling porcine NAFLD by deletion of leptin and defining the role of AMPK in hepatic fibrosis
- CASM mediates LRRK2 recruitment and activation under lysosomal stress
- Exogenous galanin alleviates hepatic steatosis by promoting autophagy via the AMPK-mTOR pathway
- Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
- Organophosphate ester flame retardants and plasticizers affect the phenotype and function of HepG2 liver cells
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Lauric acid attenuates hepato-metabolic complications and molecular alterations in high-fat diet-induced Non-alcoholic Fatty Liver Disease in rats
- Lysosomal Channels as New Molecular Targets in the Pharmacological Therapy of Neurodegenerative Diseases via Autophagy Regulation
- Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice
- BNIP3 in hypoxia-induced mitophagy: novel insights and promising target for non-alcoholic fatty liver disease
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- The Ameliorating Effects of n-3 Polyunsaturated Fatty Acids on Liver Steatosis Induced by a High-Fat Methionine Choline-Deficient Diet in Mice
- Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
- The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
- Exercise ameliorates lipid droplet metabolism disorder by the PLIN2-LIPA axis-mediated lipophagy in mouse model of non-alcoholic fatty liver disease
- BACH1 controls hepatic insulin signaling and glucose homeostasis in mice
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice
- The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy
- Phosphorylation-state dependent intraneuronal sorting of Aβ differentially impairs autophagy and the endo-lysosomal system
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Corrected and republished from: Metabolic associated liver disease
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Transcription factor EB: A potential integrated network regulator in metabolic-associated cardiac injury
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Medium- and long-chain triglyceride propofol activates PI3K/AKT pathway and inhibits non-alcoholic fatty liver disease by inhibiting lipid accumulation
- Lysosomal dysfunction and overload of nucleosides in thymidine phosphorylase deficiency of MNGIE
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Dysfunction of autophagy in high-fat diet-induced nonalcoholic fatty liver disease
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Fatty liver disease's renaming impacts on drug clinical trials
- MBOAT7 in liver and extrahepatic diseases
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Deficiency of ADAR2 ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in obese mice
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis
- Menin orchestrates hepatic glucose and fatty acid uptake via deploying the cellular translocation of SIRT1 and PPARγ
- Reduction of spermine synthase enhances autophagy to suppress Tau accumulation